Chronic Idiopathic Myelofibrosis Market See the List of Gartner Analysis Study With YM BioSciences and Sanofi, Market.us
Pune, Maharashtra, India, October 14 2022 (Wiredrelease) Prudour Pvt. Ltd --:Chronic idiopathic myelofibrosis (CIMF) is a rare, progressive blood disorder in which the bone marrow is infiltrated by fibrous tissue. This results in decreased production of normal blood cells, leading to anemia, fatigue, and an increased risk of infection. There is currently no cure for CIMF, and treatment options are limited. The CIMF market is expected to grow significantly in the next decade due to the increasing incidence of the disease and the lack of effective treatments. Current treatments are only able to manage symptoms and do not provide a…
- Date: October 14, 2022
- Author: Quintero
- Category: PharmiWeb